Enlivex Therapeutics 2024 Shareholder Meeting Fails Due to Lack of Quorum
Ticker: ENLV · Form: 6-K · Filed: Oct 31, 2024 · CIK: 1596812
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing
TL;DR
Enlivex's shareholder meeting on Oct 31st failed to happen - no quorum!
AI Summary
Enlivex Therapeutics Ltd. held its 2024 Annual General Meeting of Shareholders on October 31, 2024. The meeting was convened but was not able to proceed due to a lack of quorum. The company is organized under the laws of the State of Israel and its principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel.
Why It Matters
A lack of quorum at a shareholder meeting can indicate low investor engagement or dissatisfaction, potentially impacting future corporate decisions and governance.
Risk Assessment
Risk Level: medium — Failure to achieve quorum for a shareholder meeting can signal underlying issues with investor confidence or engagement, potentially impacting the company's ability to conduct business.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- October 31, 2024 (date) — Date of Annual General Meeting
- Israel (location) — Country of Incorporation
FAQ
What was the purpose of the October 31, 2024 meeting?
The meeting was the 2024 Annual General Meeting of Shareholders for Enlivex Therapeutics Ltd.
Why did the 2024 Annual General Meeting of Shareholders not proceed?
The meeting was not able to proceed due to a lack of quorum.
What is the company's country of incorporation?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
Where are Enlivex Therapeutics Ltd.'s principal executive offices located?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel, 7403618.
What form does this filing represent?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-10-31 16:05:13
Filing Documents
- ea0219284-6k_enlivex.htm (6-K) — 9KB
- 0001213900-24-092874.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: October 31, 2024